Prospective evaluation of the performance of [68Ga]Ga-PSMA-11 PET/CT(MRI) for lymph node staging in patients undergoing superextended salvage lymph...
Abufaraj M., Grubmüller B., Zeitlinger M., Kramer G., Seitz C., Haitel A., Baltzer P., Hacker M., Wadsak W., Pfaff S., Wiatr T., Mitterhauser M., Shariat Sh., Hartenbach M.
European Journal of Nuclear Medicine and Molecular Imaging
Vol.46, Issue10, P. 2169-2177
Опубликовано: 2019
Тип ресурса: Статья
DOI:10.1007/s00259-019-04361-0
Аннотация:
Purpose: To assess the accuracy of [68Ga]-PSMA-11 PET/CT or [68Ga]-PSMA-11 PET/MRI (PSMA-11 PET/CT(MRI)) for lymph node (LN) staging using salvage LN dissection (SLND) in patients with biochemical recurrence (BCR) after radical prostatectomy (RP). Patients and methods: In a prospective study, 65 consecutive patients who developed BCR after RP underwent SLND after PSMA-11 PET/CT(MRI) between 2014 and 2018. Extended SLND up to the inferior mesenteric artery was performed in all patients. Regional and template-based correlations between the presence of LN metastases on histopathology and whole-body PSMA-11 PET/CT(MRI) results were evaluated. The diagnostic accuracy of PSMA-11 PET/CT(MRI) was also evaluated in relation to PSA level at the time of SLND. Results: The median age of the patients at the time of SLND was 65 years (IQR 63–69 years) and the median PSA level was 1.4 ng/ml (IQR 0.8–2.9 ng/ml). Before SLND, 50 patients (77[%]) had additional therapy after RP (26.2[%] androgen-deprivation
Ключевые слова:
Biochemical recurrence; Hybrid imaging; PET/CT; PET/MRI; PSMA ligand; Salvage lymph node dissection
prostate specific membrane antigen 11 ga 68; radiopharmaceutical agent; unclassified drug; edetic acid; Glu-NH-CO-NH-Lys-(Ahx)-((68)Ga(HBED-CC)); oligopeptide; radiopharmaceutical agent; adult; aged; androgen deprivation therapy; Article; biochemical recurrence; cancer radiotherapy; cancer recurrence; cancer regression; cancer staging; diagnostic accuracy; follow up; Gleason score; histopathology; human; image quality; inferior mesenteric artery; lymph node dissection; lymph node metastasis; major clinical study; male; peroperative complication; postoperative complication; predictive value; prospective study; sensitivity and specificity; clinical trial; diagnostic imaging; lymph node metastasis; middle aged; multimodal imaging; nuclear magnetic resonance imaging; pathology; positron emission tomography-computed tomography; procedures; prostate tumor; prostatectomy; Aged; Edetic Acid; Humans; Lymphatic Metastasis; Magnetic Resonance Imaging; Male; Middle Aged; Multimodal Imaging; Oligop
Язык текста: Английский
ISSN: 1619-7089
Abufaraj M.
Grubmüller B.
Zeitlinger M.
Kramer G.
Seitz C.
Haitel A.
Baltzer P.
Hacker M.
Wadsak W.
Pfaff S.
Wiatr T.
Mitterhauser M.
Shariat Sh. Sharokh 1973-
Hartenbach M.
Абуфарай М.
Грубмüллер Б.
Зеитлингер М.
Крамер Г.
Сеитз C.
Хаител А.
Балтзер П.
Хаcкер М.
Wадсак W.
Пфафф С.
Wиатр Т.
Миттерхаусер М.
Шариат Ш. Шарох 1973-
Хартенбач М.
Prospective evaluation of the performance of [68Ga]Ga-PSMA-11 PET/CT(MRI) for lymph node staging in patients undergoing superextended salvage lymph node dissection after radical prostatectomy
Prospective evaluation of the performance of [68Ga]Ga-PSMA-11 PET/CT(MRI) for lymph node staging in patients undergoing superextended salvage lymph...
Текст визуальный непосредственный
European Journal of Nuclear Medicine and Molecular Imaging
Springer-Verlag GmbH
Vol.46, Issue10 P. 2169-2177
2019
Статья
Biochemical recurrence Hybrid imaging PET/CT PET/MRI PSMA ligand Salvage lymph node dissection
prostate specific membrane antigen 11 ga 68 radiopharmaceutical agent unclassified drug edetic acid Glu-NH-CO-NH-Lys-(Ahx)-((68)Ga(HBED-CC)) oligopeptide radiopharmaceutical agent adult aged androgen deprivation therapy Article biochemical recurrence cancer radiotherapy cancer recurrence cancer regression cancer staging diagnostic accuracy follow up Gleason score histopathology human image quality inferior mesenteric artery lymph node dissection lymph node metastasis major clinical study male peroperative complication postoperative complication predictive value prospective study sensitivity and specificity clinical trial diagnostic imaging lymph node metastasis middle aged multimodal imaging nuclear magnetic resonance imaging pathology positron emission tomography-computed tomography procedures prostate tumor prostatectomy Aged Edetic Acid Humans Lymphatic Metastasis Magnetic Resonance Imaging Male Middle Aged Multimodal Imaging Oligop
Purpose: To assess the accuracy of [68Ga]-PSMA-11 PET/CT or [68Ga]-PSMA-11 PET/MRI (PSMA-11 PET/CT(MRI)) for lymph node (LN) staging using salvage LN dissection (SLND) in patients with biochemical recurrence (BCR) after radical prostatectomy (RP). Patients and methods: In a prospective study, 65 consecutive patients who developed BCR after RP underwent SLND after PSMA-11 PET/CT(MRI) between 2014 and 2018. Extended SLND up to the inferior mesenteric artery was performed in all patients. Regional and template-based correlations between the presence of LN metastases on histopathology and whole-body PSMA-11 PET/CT(MRI) results were evaluated. The diagnostic accuracy of PSMA-11 PET/CT(MRI) was also evaluated in relation to PSA level at the time of SLND. Results: The median age of the patients at the time of SLND was 65 years (IQR 63–69 years) and the median PSA level was 1.4 ng/ml (IQR 0.8–2.9 ng/ml). Before SLND, 50 patients (77[%]) had additional therapy after RP (26.2[%] androgen-deprivation